CSIMC Recommends NHI Price Listing for 15 APIs/20 Products

At a general meeting on September 7, the Central Social Insurance Medical Council (CSIMC; Chuikyo) recommended NHI price listing for 15 APIs (active pharmaceutical ingredients)/20 products, including AstraZeneca’s proton pump inhibitor (PPI) Nexium capsule 10 mg and 20 mg (esomeprazole magnesium) and Astellas Pharma’s treatment for overactive bladder Betanis Tablet 25 mg and 50 mg (mirabegron). The adrenal hormone preparation EpiPen Injection 0.15 mg and 0.3 mg (adrenaline) will be added to the NHI price list on September 22. Other products will be included in the NHI price list on September 12.
> Read full story


Japan, US, EU Regulators Trod Different Paths to Iressa Approval; Japan’s Capabilities to Be Tested with Sakigake System


Pricing premium for the promotion of new drug development and the elimination/resolution of off-label use:

The Column

Pharma Companies in JPAC Are Searching for the Goldilocks Candidate


Belsomra Most Heavily Pitched Drug in July: Anterio Ranking(Oct.05)
Japan Hypertension Society Announces COI Guide after Diovan Woes(Oct.05)
Humanitarian Trial Data Will Be Supplementary Reference to Confirmatory Studies: Govt(Oct.05)
Drug Pricing Tomorrow: Full Interview with JMA Vice President Nakagawa(Oct.05)
Japan OTC Drug Market Logs 1st Rise in 5 Years: Fuji Keizai(Oct.05)

Most Read

Takeda Slapped with Business Improvement...
Drug Pricing Tomorrow: JMA’s Nakagawa Sa...
Active Promotion of HPV Vaccines Should ...
Chuikyo Approves Draft Framework for Pat...
GSK to Compensate for Add’l Patient Burd...

News Calendar